Browsing Tag
Gilead Sciences Inc.
5 posts
Gilead’s Bixlenvo approval extends lenacapavir from prevention into daily HIV treatment
Gilead has secured FDA approval for Bixlenvo, combining bictegravir and lenacapavir in a once-daily tablet aimed particularly at virologically suppressed adults who remain on complex multi-pill HIV regimens.
Phase 3 hepatitis C win fails to lift Atea stock against Gilead’s Epclusa
Atea’s eight-week hepatitis C regimen met Phase 3 endpoints against Epclusa, but $AVIR fell as investors questioned its commercial edge.
Could Datroway become AstraZeneca and Daiichi Sankyo’s next major oncology franchise after Enhertu?
atroway has received a positive European regulatory recommendation for first-line treatment of metastatic triple-negative breast cancer in patients unable to receive immunotherapy. The decision moves AstraZeneca PLC and Daiichi Sankyo Company, Limited closer to opening a commercially important market while increasing the strategic value of their antibody drug conjugate partnership.
How a first-in-class HDV approval could support Gilead Sciences’ long-term antiviral portfolio
Find out how Hepcludex approval could strengthen Gilead Sciences’ antiviral portfolio and reshape HDV care in the U.S.
Gilead Sciences to double down on CAR T with $7.8bn Arcellx acquisition
Find out how Gilead Sciences’ $7.8 billion Arcellx acquisition reshapes the future of anito-cel and the competitive landscape in multiple myeloma.